COMP <GO>
MRNA vs GILD // ALTMAN Z-SCORE & DEBT/EQUITY
Moderna Inc. (NASDAQ) VS. Gilead Sciences Inc. (NASDAQ) • 15-METRIC TALLY: MRNA 2
— GILD 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRNA
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
balance-sheet
15.07
LAST: $170.68 (+3.06%) • MKT CAP: $205.35B
balance-sheet
5.87
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. GILD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | GILD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | 78.80% | -23.50 | GILD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | 21.00% | -55.10 | GILD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.32% | 4.60% | -6.92 | GILD | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.00% | -94.00 | GILD | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.90% | -88.90 | GILD | /net-margins <GO> |
| Revenue Growth (YoY) | -39.90% | 2.40% | -42.30 | GILD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.95% | -1.95 | GILD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 15.07 | 5.87 | +9.20 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | GILD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 64.3 | -6.60 | GILD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.88 | +0.22 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 22.4x | +9.60 | GILD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $205.35B | -$116.42B | GILD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | GILD REV | MRNA GROSS % | GILD GROSS % | MRNA FCF | GILD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $29.44B | 55.3% | 78.8% | -$2.06B | $9.46B |
| FY 2024 | $3.24B | $28.75B | 54.8% | 78.3% | -$4.05B | $10.30B |
| FY 2023 | $6.85B | $27.12B | — | — | -$3.43B | $6.79B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
GILD // BETA 0.88